OR WAIT null SECS
The companies will aim to establish clinical and commercial supply agreements for Plus Therapeutics’ RNL-liposome drug product at the appropriate stage of development.
Piramal Pharma Solutions (PPS), Piramal Pharma Limited’s contract development and manufacturing organization, announced on March 23, 2021 that it has entered into a master services agreement with Plus Therapeutics, a US-based clinical-stage pharmaceutical company, under which Piramal will offer development, manufacture, and supply services for Plus Therapeutics’ rhenium nanoliposome (RNL)-liposome intermediate drug product.
Under the terms of the agreement, transfer of analytical methods, development of microbiological methods, process transfer and optimization, intermediate drug product manufacturing, and stability studies will be performed at PPS’ drug product facility in Lexington, KY, PPS said in a company press release. The companies will aim to establish clinical and commercial supply agreements for the drug product at the appropriate stage of development through the agreement.
“We are excited to partner with Plus Therapeutics. We believe that this represents the start of a long, collaborative, and mutually beneficial relationship that will address our ultimate objective of reducing the burden of disease on patients,” said Peter DeYoung, CEO, Pharma Solutions, Piramal Pharma Limited, in the press release.
“This agreement represents another significant milestone for Plus, as we work to advance development of RNL as a novel treatment option for patients diagnosed with glioblastoma,” said Marc Hedrick MD, president and CEO of Plus Therapeutics, in the press release. “The team at PPS has the knowledge, experience, and expertise to support our needs, both now and in the future as we advance RNL towards regulatory approval.”